Lördag 2 Augusti | 10:51:15 Europe / Stockholm

Prenumeration

2025-07-21 08:21:00

Redeye updates its forecasts and fair value range for Stille following the Q2 report and the acquisition of UK-based Surgical Holdings. The company has faced headwinds in H1 but is now positioned for a rebound in H2, currently trading at around 13x 2025e EV/EBITDA.

Read more and download the Research Update.
 
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
 
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/